Drug
Serelaxin clinical trials
Also written RLX030.
- studies test it
- 17
- open now
- 0
- in phase 3
- 3
- first study started
- 2005
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2014 (6)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 2 |
| 2012 | 2 |
| 2013 | 4 |
| 2014 | 6 |
| 2016 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 12
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 1
Novartis Pharmaceuticals (13) · Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies (3) · University of Edinburgh (1)
Often tested with
Tested in the same studies.
Terlipressin acetate (1) · Terlipressin (1)
Studies
Open first, then newest update. How each study uses serelaxin is read from its arms, and is right about nine times in ten.
Testing it · 17
- PK of Serelaxin in Severe Renal Impairment and ESRDCompletedPhase 1Novartis PharmaceuticalsNCT01875523Written as Serelaxin
- Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)CompletedPhase 2Novartis PharmaceuticalsNCT01546532Written as RLX030
- Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHFTerminatedPhase 3Novartis PharmaceuticalsNCT02007720Written as Serelaxin
- Study of the Vascular Effects of SerelaxinCompletedPhase 2Novartis PharmaceuticalsNCT01979614Written as Serelaxin
- Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart FailureTerminatedPhase 2Novartis PharmaceuticalsNCT02151383Written as Serelaxin
- Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) PatientsTerminatedPhase 3Novartis PharmaceuticalsNCT02064868Written as Serelaxin
- Serelaxin To Lower Portal PressureCompletedPhase 2University of EdinburghNCT02669875Written as Serelaxin
- Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart FailureTerminatedPhase 2Novartis PharmaceuticalsNCT02625922Written as Serelaxin
- Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHFCompletedPhase 3Novartis PharmaceuticalsNCT01870778Written as RLX030
- Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart FailureCompletedPhase 2Novartis PharmaceuticalsNCT01982292Written as RLX030 (serelaxin)
- An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal HypertensionCompletedPhase 2Novartis PharmaceuticalsNCT01640964Written as Serelaxin (RLX030)
- Safety and Efficacy of RLX030 in Pregnant Women With Pre- EclampsiaTerminatedPhase 2Novartis PharmaceuticalsNCT01566630Written as RLX030
- Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) PatientsCompletedPhase 2Novartis PharmaceuticalsNCT02002702Written as Serelaxin
- Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart FailureCompletedPhase 2Novartis PharmaceuticalsNCT01543854Written as RLX030
- Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of LaborCompletedPhase 2Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companiesNCT00259103Written as Serelaxin
- Recombinant Human Relaxin for the Treatment of Decompensated CHFTerminatedPhase 2Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companiesNCT00406575Written as Recombinant human relaxin (rhRlx)
- Evaluation of the Safety of Relaxin in PreeclampsiaSuspendedPhase 1Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companiesNCT00333307Written as recombinant human relaxin
Codes
What other systems call serelaxin · ClinicalTrials.gg INT018284
- UNII (FDA) W0122B976YSERELAXINConfirmed FDA, Wikidata
- Wikidata Q7453086serelaxinConfirmed FDA, Wikidata
- NCI Thesaurus C152342SerelaxinOne source FDA
- DrugBank DB05794One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | W0122B976Y | SERELAXIN | Confirmed FDA, Wikidata |
| Wikidata | Q7453086 | serelaxin | Confirmed FDA, Wikidata |
| NCI Thesaurus | C152342 | Serelaxin | One source FDA |
| DrugBank | DB05794 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.